Optimizing hypertension andvascular health: Focus on ethnicity

2004, Heart and Strok Facts. American Heart Association McCord, 1990, Excess mortality in Harlem, N Engl J Med., 322, 173, 10.1056/NEJM199001183220306 2003, 35 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 1997, The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (INC VI), Arch Intern Med., 157, 2413, 10.1001/archinte.1997.00440420033005 Falkner, 1990, Differences in blacks and whites with essential hypertension: Biochemistry and endocrine. State of the art lecture, Hypertension, 15, 681, 10.1161/01.HYP.15.6.681 Chrysant, 1979, Racial differences in pressure, volume and renin interrelationships in essential hypertension, Hypertension, 1, 136, 10.1161/01.HYP.1.2.136 Cooper, 1997, The prevalence of hypertension in seven populations of west African origin, Am J Public Health, 87, 160, 10.2105/AJPH.87.2.160 Materson, 1995, Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, Am J Hypertens, 8, 189, 10.1016/0895-7061(94)00196-I Lonn, 2004, Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved leftventricular ejection fraction: A substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial, J Am Coll Cardiol., 43, 2200, 10.1016/j.jacc.2003.10.073 Berthet, 2004, Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial, Blood Press, 13, 7, 10.1080/08037050410029605 Konstam, 1992, Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricu lar dysfunction in patients withheart failure: SOLVD Investigators, Circulation, 86, 431, 10.1161/01.CIR.86.2.431 Cohn, 1990, Heart failure with normal ejection fraction: The V-HeFT study. Veterans Administration Cooperative Study Group, Circulation, 81, III48 Kostis, 2004, Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial, Am J Hypertens, 17, 103, 10.1016/j.amjhyper.2003.09.014 Julius, 2004, Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The LIFE study, J Am Coll Cardiol., 43, 1047, 10.1016/j.jacc.2003.11.029 Cushman, 2002, Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLRAT), J Clin Hypertens, 4, 393, 10.1111/j.1524-6175.2002.02045.x 2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: TheAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLRAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981 Douglas, 2003, Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of theInternational Society on Hypertension in Blacks, Arch Intern Med., 163, 525, 10.1001/archinte.163.5.525 Chobanian, 2003, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2 Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK Trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421 Douglas, 2003, ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AAS K) trial, Kidney Int., 83, S74, 10.1046/j.1523-1755.63.s83.15.x Agodoa, 2001, Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial, JAMA, 285, 2719, 10.1001/jama.285.21.2719 Guasch, 1997, Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy, J Am Soc Nephrol., 8, 793, 10.1681/ASN.V85793 Bakris, 1997, Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans, Hypertension, 29, 744, 10.1161/01.HYP.29.3.744 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 Hebert, 1997, Effects of blood pressure control on progressive renal disease in blacks and whites: Modification of Diet in Renal Disease Study Group, Hypertension, 30, 428, 10.1161/01.HYP.30.3.428 Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6 Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension, N Engl J Med., 338, 645, 10.1056/NEJM199803053381003 Berl, 2003, Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy, Ann Intern Med., 138, 542, 10.7326/0003-4819-138-7-200304010-00010